ES El objetivo de este proyecto es el estudio de las necesidades de usuario para el diseño y desarrollo de una aplicación móvil con la finalidad de visitar los monumentos más emblemáticos de ...Valencia. Sirve como guía para los turistas que quieran obtener información sobre éstos, donde podrán seleccionar los que más les haya gustado así como guiarlos hasta dicho monumento mediante un mapa. Lo interesante, además, es que el usuario puede consultar información proporcionada por fuentes oficiales como el Ayuntamiento de Valencia gracias a la APIRest implementada con PHP que permite a la aplicación mostrar esta información.
CA L’objectiu d’aquest projecte és l’estudi de les necessitats de l’usuari per al disseny i desenvolupament d’una aplicació mòbil amb la finalitat de visitar els monuments més emblemàtics de València. Serveix com a guia per als turistes que volen obtindre informació d’aquests, a on podran seleccionar els que més les haja agradat així com guiar-los fins al monument mitjançant un mapa. Lo interesant, a més a més, és que l’usuari pot consultar informació proporcionada per fonts oficials com l’Ajuntament de València gràcies a la APIRest implementada amb PHP que permet a la aplicació mostrar aquesta informació.
EN The objetive of this project is the study of user needs for the design and development of a mobile application in order to visit the most symbolic monuments in Valencia. It’s useful as a guide for tourists who want to get information about them, and they will be able to select their favourites monuments and guide them with a map. The interesting thing is that the user can get the information from official resources like “Ayuntamiento de Valencia” due to the APIRest that is done with PHP and allows the application to show this information.
EN The objetive of this project is the study of user needs for the design and development of a mobile application in order to visit the most symbolic monuments in Valencia. It’s useful as a guide for tourists who want to get information about them, and they will be able to select their favourites monuments and guide them with a map. The interesting thing is that the user can get the information from official resources like “Ayuntamiento de Valencia” due to the APIRest that is done with PHP and allows the application to show this information.
ES El objetivo de este proyecto es el estudio de las necesidades de usuario para el diseño y desarrollo de una aplicación móvil con la finalidad de visitar los monumentos más emblemáticos de Valencia. Sirve como guía para los turistas que quieran obtener información sobre éstos, donde podrán seleccionar los que más les haya gustado así como guiarlos hasta dicho monumento mediante un mapa. Lo interesante, además, es que el usuario puede consultar información proporcionada por fuentes oficiales como el Ayuntamiento de Valencia gracias a la APIRest implementada con PHP que permite a la aplicación mostrar esta información.
CA L’objectiu d’aquest projecte és l’estudi de les necessitats de l’usuari per al disseny i desenvolupament d’una aplicació mòbil amb la finalitat de visitar els monuments més emblemàtics de València. Serveix com a guia per als turistes que volen obtindre informació d’aquests, a on podran seleccionar els que més les haja agradat així com guiar-los fins al monument mitjançant un mapa. Lo interesant, a més a més, és que l’usuari pot consultar informació proporcionada per fonts oficials com l’Ajuntament de València gràcies a la APIRest implementada amb PHP que permet a la aplicació mostrar aquesta informació.
The PI3K/AKT/mTOR pathway is frequently overactivated in endometrial cancer (EC). We assessed the efficacy of ABTL0812, a novel first-in-class molecule presenting a unique mechanism of action ...inhibiting this pathway.
We investigated the effects of ABTL0812 on proliferation, cell death and modulation of intracellular signaling pathways in a wide panel of endometrioid and non-endometrioid cell lines, an inducible PTEN knock-out murine model, and two patient-derived xenograft murine models of EC. Then, TRIB3 expression was evaluated as potential ABTL0812 pharmacodynamic biomarker in a Phase 1b/2a clinical trial.
ABTL0812 induced an upregulation of TRIB3 expression, resulting in the PI3K/AKT/mTOR axis inhibition and autophagy cell death induction on EC cells but not in healthy endometrial cells. ABTL0812 treatment also impaired PTEN knock-out cells to progress from hyperplasia to cancer. The therapeutic effects of ABTL0812 were demonstrated in vivo. ABTL0812 increased TRIB3 mRNA levels in whole blood samples of eight EC patients, demonstrating that TRIB3 mRNA could be used as a pharmacodynamic biomarker to monitor the ABTL0812 treatment.
ABTL0812 may represent a novel and highly effective therapeutic agent by inducing TRIB3 expression and autophagy in EC patients, including those with poorer prognosis.
Display omitted
•ABTL0812 is a small molecule inhibitor and is an effective therapeutic option for high-risk endometrial cancer patients.•ABTL0812 acts by inducing TRIB3 expression, inhibiting the PI3K/AKT/mTOR axis, and promoting autophagy cell death.•In preclinical models, ABTL0812 kills endometrial cancer cells but not healthy endometrial cells.•ABTL0812 stops hyperplasic lesions to progress to cancer.
Colonomics is a multi-omics dataset that includes 250 samples: 50 samples from healthy colon mucosa donors and 100 paired samples from colon cancer patients (tumor/adjacent). From these samples, ...Colonomics project includes data from genotyping, DNA methylation, gene expression, whole exome sequencing and micro-RNAs (miRNAs) expression. It also includes data from copy number variation (CNV) from tumoral samples. In addition, clinical data from all these samples is available. The aims of the project were to explore and integrate these datasets to describe colon cancer at molecular level and to compare normal and tumoral tissues. Also, to improve screening by finding biomarkers for the diagnosis and prognosis of colon cancer. This project has its own website including four browsers allowing users to explore Colonomics datasets. Since generated data could be reuse for the scientific community for exploratory or validation purposes, here we describe omics datasets included in the Colonomics project as well as results from multi-omics layers integration.
Endometrial carcinomas, the most common malignant tumour of the female genital tract, are usually diagnosed at an early stage with uterine‐confined disease and an overall favourable prognosis. ...However, up to 20% of endometrial carcinomas will end up in recurrent disease, associated with a drop in survival and representing the major clinical challenge. Management of this group of risk patients relies on robust biomarkers that may predict which endometrial carcinomas will relapse. For this, we performed a proteomic analysis comparing primary lesions with recurrences and identified ANXA2 as a potential biomarker associated with recurrent disease that we further validated in an independent series of samples by immunohistochemistry. We demonstrated in vitro a role for ANXA2 in the promotion of metastasis rather than interfering with sensitivity to radio/chemotherapy. In addition, ANXA2 silencing resulted in a reduced metastatic pattern in a mice model of endometrial cancer dissemination, with a limited presence of circulating tumor cells. Finally, a retrospective study in a cohort of 93 patients showed that ANXA2 effectively predicted those endometrioid endometrial carcinomas that finally recurred. Importantly, ANXA2 demonstrated a predictive value also among low risk Stage I endometrioid endometrial carcinomas, highlighting the clinical utility of ANXA2 biomarker as predictor of recurrent disease in endometrial cancer. Retrospective and prospective studies are ongoing to validate ANXA2 as a potential tool for optimal stratification of patients susceptible to receive radical surgery and radio/chemotherapy.
What's New?
Endometrial carcinoma is usually diagnosed early, with a favorable prognosis. However, even in these early cases, the relapse rate can be as high as 20%. Thus it would be helpful to have a biomarker that could predict which tumors are likely to recur, and which patients might benefit from more aggressive treatment. In this clinical study, the authors found that a protein called annexin A2 (ANXA2) may provide just such a biomarker. Interestingly, they also found that ANXA2 is involved in the ability of endometrial carcinomas to metastasize.
PDF